One inventor, three fields: what actually transfers between bioelectronics, energy storage and vehicle power

The question I get asked first

Three granted patent families in three fields that share no market, no customer and no regulator: a bioelectronic medical device, a battery–supercapacitor storage architecture, and a multi-source power system for vehicles. The reasonable reaction is scepticism. One person working across three unrelated industries usually means one person working shallowly in three.

So this is the honest answer to what connects them, written for someone deciding whether the portfolio is coherent or scattered. There is a real through-line. It is narrower than "innovation" and more useful than a slogan.

The through-line: controlled electrical delivery into a system that resists it

Every one of the three is the same problem in a different medium. You have a source of electrical energy. You have a load that will be damaged, or will behave badly, if you deliver that energy carelessly. The invention in each case is the conditioning stage in between — the part that decides waveform, magnitude and timing so the load gets what it can use and not what it cannot.

  • eMedica. The load is tissue. Deliver current outside a narrow window of voltage, current and frequency and you either do nothing or you do harm. The device is a controlled waveform generator with the safety envelope built into the claim.
  • Hybrid Power Pack. The load is a battery. Deliver — or demand — current in sharp peaks and it heats quadratically and degrades. A supercapacitor buffer absorbs the peaks so the cell sees a smoothed profile.
  • OMNIA Drive. The loads are a drivetrain and a battery, and the difficulty is on the supply side: several small, intermittent, mutually incompatible sources. One power processing unit conditions all of them into two clean outputs.

Same discipline: the thing being protected is the interface, not the source and not the load. That is one skill, applied three times, and it is why the claim language across the three families rhymes even though the subject matter does not.

What genuinely transfers

Waveform control as the object of the invention. In all three, the novelty is in what the electricity is shaped into, not in the components that shape it. That is also why all three proceeded to grant: the claims recite behaviour and bounds, not a parts list.

Thinking in envelopes rather than peak numbers. A medical device is specified by the range it must stay inside. A pack is specified by the current and temperature it must not exceed. A harvesting system is specified by the range of inputs it must accept. In each field the useful specification is a bounded region, and the failure mode is the same — someone quotes the best point in the region as though it were the whole region.

The habit of naming conditions with every number. Ten thousand cycles means nothing without the temperature. A microamp figure means nothing without the tissue impedance it was measured across. Carrying the conditions inline is not caution; it is the only way a number stays true when it travels.

What does not transfer, and pretending otherwise is where people come unstuck

Being right about the physics in one field buys you nothing in another field's evidence standard, and this is the distinction I would most want a licensing counterparty to hear me make.

In energy storage, a claim is settled by measurement. Build the pack, instrument it, run it, publish the conditions. The physics is not in dispute; the numbers are, and numbers can be produced.

In medicine, measurement is the beginning. A device that does exactly what its specification says can still fail to help a patient, and only a controlled trial distinguishes the two. No amount of power-electronics rigour substitutes for that, and an inventor who imports confidence from one field into the other is doing the single most damaging thing available to him.

This is why eMedica is described as an adjuvant device used alongside prescribed treatment under medical supervision, and why its evidence is described as observational where it is observational. The engineering is strong. The clinical evidence base is at an earlier stage than the engineering, and saying so is not modesty — it is the only description that survives being checked.

Why one person, and not a team in each field

Because it was bootstrapped. There was no research budget and no institution, which imposed a discipline that turned out to be useful: every idea had to be reducible to something that could be built and tested by a small group, and anything that could not be tested was not pursued. Three families came out of that. Others did not, and the ones that did not were dropped rather than dressed up.

The same constraint explains the shape of the portfolio — the patents are held by the individual inventor and are not assigned to any company. That is unusual, and for a counterparty it is a simplification: there is no cap table, no board and no co-owner between an offer and a signature.

What this means for anyone evaluating the portfolio

Judge each family on its own register entries and its own evidence, because they do not borrow credibility from each other and they are not offered as though they do. What the common authorship gives you is not a reason to trust the numbers; it is a reason to expect them to be described the same way — bounded, conditioned, and separated from what has not been shown.

Grants are in force across India, the United States, Japan, South Korea, Canada, Mexico, Australia, Vietnam, Saudi Arabia, South Africa, Germany, the United Kingdom, Switzerland, Russia and Kazakhstan. Each is a national register entry with a number that can be checked in an afternoon. Every entry in the public register carries its grant number and its grant date, for the plain reason that a portfolio a reader can verify line by line is worth more than one described generously.

Measure everything. Validate everything. Improve continuously.

Related
The Electrical Body: what membrane voltage does, and what applied current can and cannot do
Designing an evidence pathway for an adjuvant device: what we have, what it shows, and what comes next
How I verify a technical claim before publishing it: the four-layer rule
Can you harvest the Earth's magnetic field?
Hybrid Power Pack — nextgenpowerpack.com · OMNIA Drive — roheraindustries.com · eMedica — emedica.in

Hemant K. Rohera is an independent inventor and engineer in Pune, India, sole named inventor on three granted patent families — bioelectronic medical devices, hybrid energy storage and vehicle power electronics. All three families are available for licensing, assignment or joint development. ORCID 0009-0005-3275-1743.

The complete patent register, with a grant number and grant date for every entry, and the research record, with abstracts and DOIs for the deposited notes, are published at hemant-rohera.vercel.app/patent-register.html and hemant-rohera.vercel.app/research.html.

Comments

Post a Comment

Popular posts from this blog

Who is Hemant Rohera? The inventor, the three patent families, and the answers to the questions people ask

Hemant K. Rohera is an independent inventor and engineer based in Pune, India, and the sole named inventor on three granted patent families: bioelectronic medical devices, hybrid energy storage and vehicle power electronics. Grants are in force in India, the United States, Japan, South Korea, Canada, Mexico, Australia, Vietnam, Saudi Arabia, South Africa, Russia, Kazakhstan, Germany, the United Kingdom and Switzerland. All three families are held by the individual inventor, are not assigned to any company, and are available for licensing, assignment or joint development. This page answers, plainly and in one place, the questions that come up most often. Every figure carries the register entry or report it comes from. Who is Hemant Rohera? Hemant K. Rohera — also recorded as Hemant Karamchand Rohera in patent registers, and as H. K. Rohera — is an independent inventor and engineer in Pune, Maharashtra, India, with more than twenty-nine years in research and development across bio...
Read more

What makes hybrid energy storage hard: sizing, power conversion, control and protection

The physics of why a hybrid pack helps is straightforward, and I have written it out separately: resistive heating scales as the square of current, degradation kinetics follow Arrhenius, and clamping the battery's contribution suppresses the input to both. That argument takes about a page and it is not in dispute. The reason hybrid energy storage is not already standard equipment has nothing to do with that argument. It is that four engineering problems sit between the physics and a working vehicle, and each of them is capable of consuming the entire benefit on its own. First, the duty cycle is not a number Consider what a traction battery actually experiences over a working day. Average power draw across a city bus route might sit at 30–40 kW . Peak demand during acceleration can reach 200 kW or more . Regenerative braking sends a comparable spike back the other way. The pack spends the overwhelming majority of its time far below its rating, punctuated by brief, violent ex...
Read more

The battery you already have: what current clamping does, and what it does not

Most conversations about extending battery life start with the cell. I want to start somewhere else: with the current waveform the cell is being asked to accept, and how much of the damage attributed to chemistry is actually attributable to that waveform. This is the engineering case behind the Hybrid Power Pack patents. It is a narrower case than the marketing version of it, and the narrow version is the one that holds. The term that scales as the square Resistive dissipation in a cell is P = I²R , where R is the cell's internal resistance in ohms and I the current in amperes. The square is the entire point. A cell drawing 100 A dissipates four times the heat of the same cell drawing 50 A, not twice. Now put a number on a duty cycle. A battery cycled at a continuous 1.0C versus the same battery held to 0.3C by an upstream buffer: P 0.3 / P 1.0 = (0.3 / 1.0)² = 0.09 A 91% reduction in the resistive heating term. I want to be precise about what that figure is. It is ...
Read more